Published on
February 21, 2019
- 11:00 GMT
Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta™ for the Acute Treatment of Migraine ...
Long-term one-year dosing reaffirmed well-tolerated safety profile Qtrypta showed robust and rapid relief of migraine pain, an effect that was consistent throughout the chronic treatment period NDA submission expected in Q4 2019 for the first …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
